Does Vitamin Shoppe, Inc. Have a Healthier Future Than GNC Holdings Inc.?

Both Vitamin Shoppe and GNC recently reported earnings. And while both companies saw shares plummet after the news, Vitamin Shoppe’s results point to a quicker recovery than rival GNC's.

May 28, 2014 at 9:30PM

 Following the release of their latest quarterly earnings results, the market whipped shares of health and wellness retailers GNC Holdings (NYSE:GNC) and Vitamin Shoppe (NYSE:VSI) on May 6 and May 7. GNC's first quarter of fiscal 2014 had weak sales, which were attributed in part to a drop in demand for its diet products, which have lately fallen out of favor with consumers. However, Vitamin Shoppe's results seem to imply  more positive momentum for the remainder of the year. The company posted stronger sales during the first-quarter than its rival, especially in its direct-sales channel. While both companies faced a challenging quarter, Vitamin Shoppe seems to offer shareholders a better investment value going forward.

Market praises Vitamin Shoppe's management 
While top-line revenue showed strength, higher expenses were noted during the first quarter, mostly due to acquisition-related expenses and higher depreciation. Some of the first quarter's highlights are:

  • Total net sales for the quarter increased 10.3% to $307.8 million versus $279.1 million in the same quarter in 2013.
  • Total comp sales grew by 3.6% and the first quarter marked the 34th consecutive quarter of positive growth.
  • The e-commerce (direct-sales) channel posted a 17% increase in revenue
  • Net income was $20.5 million, down by $288,000
  • Diluted EPS dropped a penny to $0.67 from $0.68 in the same period in 2013
  • .

 Despite some short term issues, analysts at Barclays had high praise for Vitamin Shoppe's management and their focus on diversifying the company's business as well as the stable results achieved given the current environment. Two days after the first-quarter earnings release, they upgraded the stock to overweight from equal weight. The company is known for its broad product offerings much like its main rival GNC. Its offerings include vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. Vitamin Shoppe sells about 900 brands that include both independent brand names and its own proprietary brands.

As of March 29, there were 667 Vitamin Shoppe stores in operation, and direct sales to consumers are made through the company's and websites. During the quarter, the company opened nine stores, including one in Canada. Since the first quarter in 2013, Vitamin Shoppe has added 46 new stores and expects to open 60 additional locations during 2014.

How is the competition feeling in this challenging market?
In GNC's first quarter ended on March 31, the company reported weaker top-line results than its smaller rival Vitamin Shoppe. Consolidated revenue rose 1.9% to $677.3 million; the retail segment's revenue increased 3.1%, but the franchise and manufacturing segments declined by 1.4% and 2.2%, respectively. A decline of 0.7% in comp-store sales was blamed on bad winter weather during January and February.

While net income declined by 3.7% to $69.9 million, the company reported diluted EPS of $0.75, an increase of 2.7% compared to the same period last year. Management attributed the results to negative publicity about vitamins and supplements and weakness in third-party diet and pre-workout products. While these trends are expected to continue in the next few quarters, the company is responding by focusing on growing products categories such as fitness, enhanced marketing efforts, and offering value to customers through its member pricing program.

Another competitor in the vitamin and supplement space is CVS Caremark (NYSE:CVS), which has a broader selection of products for sale plus a retail pharmacy, its main revenue driver. The company's first quarter of fiscal 2014 had net revenue of $32.7 billion, up by 6.3% compared to the same period last year; the operating profit rose by 19.5% to about $2 billion. Comp-store sales increased during the quarter by 1.4% compared to 2013's first quarter; and while pharmacy same-store sales rose 3.8%, front store-same store sales dropped by 3.8%.

Both pharmacy and front store were negatively affected by the winter weather and a weaker-than-expected flu season, especially when compared to last year. While prescription volumes were negatively affected by 180 to 200 basis points, overall total same-store sales increased due to stronger prescription volumes and higher prices for brand-name drugs.

Foolish Takeaway
The Vitamin Shoppe is showing more optimism about its growth prospects for the remainder of 2014 than some of its competitors and is the better choice for investors. Shares trade at 15.8 times 2015 earnings and have a five-year expected PEG ratio of approximately 1.5.

Management is showing sound judgment by emphasizing and investing in an e-commerce strategy for its products, which are well suited for online shopping. Retail comp-store sales for 2014 are expected to grow by low- to mid-single digits; total comp-store sales, including e-commerce sales, are expected to grow in the mid-single digits.

GNC is more cautious about the rest of 2014, with same-store sales expected to stay flat or increase by low-single digits. It's been struggling lately, having missed market earnings estimates in the past two quarters. However, it is expanding its business abroad where it can encounter less competitive pressure. Managing costs and product pricing is critical for GNC, as well as Vitamin Shoppe, because a larger player, like CVS, with more competitive prices could lure some of its customers away.

Your credit card may soon be completely worthless
The plastic in your wallet is about to go the way of the typewriter, the VCR, and the 8-track tape player. When it does, a handful of investors could stand to get very rich. You can join them -- but you must act now. An eye-opening new presentation reveals the full story on why your credit card is about to be worthless -- and highlights one little-known company sitting at the epicenter of an earth-shaking movement that could hand early investors the kind of profits we haven't seen since the dot-com days. Click here to watch this stunning video.


Eileen Rojas has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 10:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers